Norwegian Coronavirus Disease 2019 Study

• Status: Active, not recruiting
• Trial end date: 2025-03-03
• Target enrollment: 0
• Participant gender: All

Summary

In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Akershus
• Treatments: Chloroquine; Chloroquine diphosphate; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Hospitalised

• Adults 18 year or older

• Moderately severe disease (NEWS score ≤ 6)

• SARS-CoV-2 positive nasopharyngeal swab

• Expected time of admission > 48 hours

• Signed informed consent must be obtained and documented according to ICH GCP, and national/local regulations.

Exclusion Criteria:

• Requiring ICU admission at screening

• History of psoriasis

• Known adverse reaction to hydroxychloroquine sulphate

• Pregnancy

• Prolonged QT interval (>450 ms)